Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OligoG in Cystic Fibrosis
NCT02157922Phase 2Completed
- Sponsor
- AlgiPharma
- Start
- Oct 2014
- Primary completion
- Jan 2017
- Modality
- Oligosaccharide
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of OligoG in cystic fibrosis (CF) (2 arms), sponsored by AlgiPharma. Primary endpoint: Forced Expiratory Volume in 1 second at 28 days. Started Oct 2014; status: completed.
02
Drugs
OligoG
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02157922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157922.